Immunome (IMNM) Non-Current Deffered Revenue (2019 - 2024)

Immunome has reported Non-Current Deffered Revenue for 5 years, with the latest figure at $2.2 million in Q1 2024.

• For the quarter ending Q1 2024, Non-Current Deffered Revenue fell 76.56% year-over-year to $2.2 million; the trailing twelve-month figure through Mar 2024 stood at $2.2 million (down 76.56% YoY), and the FY2023 full-year result was $5.5 million, changed N/A from the prior year.
• Non-Current Deffered Revenue for Q1 2024 stood at $2.2 million, down from $5.5 million in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $9.4 million in Q1 2023, with the low at $3000.0 in Q2 2021.
• Historically, Non-Current Deffered Revenue has averaged $2.3 million across 4 years, with a median of $12000.0 in 2021.
• Annual changes were most pronounced in 2021 — Non-Current Deffered Revenue jumped 50.0% — and 2024, when it tumbled 76.56%.
• Immunome's Non-Current Deffered Revenue stood at $8000.0 in 2020, then jumped by 50.0% to $12000.0 in 2021, then soared by 45641.67% to $5.5 million in 2023, then tumbled by 59.77% to $2.2 million in 2024.
• The last three Non-Current Deffered Revenue figures came in at $2.2 million (Q1 2024), $5.5 million (Q4 2023), and $2.9 million (Q3 2023), per Business Quant data.